Loading...

CARM CARISMA THERAPEUTICS INC US FDA Inspections 8-K Filing

CRSM

CRM

CARISMA THERAPEUTICS INC

(CARM)

2023 8-K

Show Summary

Show Summary

Merger of Equals

Listing Compliance

Nasdaq Delisting Notice

Clinical Trial Update

Nasdaq Compliance Notice

Management Change

Workforce Reduction

Financial Results

Financial Results Announcement

Termination of Manufacturin...

Resignations and Appointments

Annual Meeting Results

Retention Grants

Financial Results Announcement

Financial Results Announcement

Financial Results Announcement

Clinical Trial Results

Financial Results Announcement

Annual Meeting Results

Agreement with Jefferies LLC

Financial Results Announcement

Merger of Equals

Special Cash Dividend and C...

Stock Split and Special Div...

Earnings Reports

Nasdaq Exception for Merger

Merger Agreement Amendment

Merger Agreement and Appoin...

Merger of Equals

Merger Agreement

Delisting Notice

External Links:

Carisma Therapeutics Inc. announced preliminary findings from their Phase 1 clinical trial of CT-0508, a treatment for HER2 overexpressing cancers, showing positive results in terms of safety and efficacy.

AI Assistant

CARISMA THERAPEUTICS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.